Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solithromycin in Pediatric CABP
NCT02605122Phase 3Terminated
- Sponsor
- Melinta Therapeutics
- Start
- Apr 2016
- Primary completion
- Mar 2018
- Modality
- RNA-Targeting Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of solithromycin in community-acquired bacterial pneumonia (CAP), sponsored by Melinta Therapeutics. Started Apr 2016; status: terminated.
02
Drugs
solithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02605122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605122.